Jazz Pharma Q1 EPS Beats, Revenue +19%

Jazz Pharmaceuticals reported Q1 adjusted EPS $6.34, topping consensus $4.62 by $1.72.
Revenue reached $1.07 billion, up 19% YoY and beating the $981.08 million estimate.
Shares jumped 4.8% in after‑hours trading; company reaffirmed FY2026 revenue guidance of $4.25‑$4.5 billion.
Xywav revenue $408.2 million (+18%); Epidiolex $249.8 million (+15%); Zepzelca $101 million (+60%).